newsfilter
← Latest News
GlobeNewswire·

Galecto to Highlight GB3226 Program at ASH 2025

Two Presentations at ASH 2025 to highlight preclinical data and clinical development plans for GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for the treatment of acute myeloid leukemia (AML) BOSTON, Nov. 03, 2025